HC Wainwright Reiterates “Buy” Rating for Global Blood Therapeutics (GBT)
Global Blood Therapeutics (NASDAQ:GBT)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Wednesday, November 28th, Marketbeat reports. They currently have a $150.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 230.03% from the stock’s previous close.
Several other analysts also recently commented on GBT. BidaskClub downgraded shares of Global Blood Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $96.00 target price on shares of Global Blood Therapeutics in a report on Thursday, August 2nd. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $75.00 target price on shares of Global Blood Therapeutics in a report on Sunday, August 5th. SunTrust Banks set a $70.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Sunday, August 5th. Finally, Piper Jaffray Companies started coverage on shares of Global Blood Therapeutics in a report on Monday, August 6th. They issued an “overweight” rating and a $80.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $83.20.
Shares of GBT stock traded down $1.17 on Wednesday, hitting $45.45. The stock had a trading volume of 3,941,771 shares, compared to its average volume of 847,093. The company has a market cap of $1.65 billion, a P/E ratio of -16.47 and a beta of 3.65. Global Blood Therapeutics has a 12-month low of $30.15 and a 12-month high of $68.05.
A number of hedge funds and other institutional investors have recently bought and sold shares of GBT. State of Wisconsin Investment Board increased its stake in shares of Global Blood Therapeutics by 40.6% in the second quarter. State of Wisconsin Investment Board now owns 52,300 shares of the company’s stock worth $2,364,000 after purchasing an additional 15,100 shares in the last quarter. Nexthera Capital LP increased its stake in shares of Global Blood Therapeutics by 28.2% in the second quarter. Nexthera Capital LP now owns 404,092 shares of the company’s stock worth $18,265,000 after purchasing an additional 88,945 shares in the last quarter. Botty Investors LLC increased its stake in shares of Global Blood Therapeutics by 45.7% in the third quarter. Botty Investors LLC now owns 129,435 shares of the company’s stock worth $4,919,000 after purchasing an additional 40,595 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of Global Blood Therapeutics in the second quarter worth about $2,680,000. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Global Blood Therapeutics by 19.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 23,669 shares of the company’s stock worth $1,070,000 after purchasing an additional 3,900 shares in the last quarter.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Featured Story: Return on Investment (ROI)
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.